Clinical and pharmacokinetic profiles of digoxin immune Fab in four patients with renal impairment
- PMID: 1815424
- DOI: 10.1177/106002809102501205
Clinical and pharmacokinetic profiles of digoxin immune Fab in four patients with renal impairment
Abstract
Minimal pharmacokinetic data on digoxin immune Fab are currently available, especially in patients with impaired renal function. The serum concentration-time profiles of total digoxin, free digoxin, and digoxin immune Fab in four patients with moderate to severe renal impairment who received digoxin immune Fab are presented. The calculated elimination half-life of digoxin immune Fab was 25-73 hours. The calculated elimination half-life of total digoxin was 24-72 hours. Free digoxin concentrations rebounded to a peak of 1-2.9 ng/mL 44-97 hours after the administration of digoxin immune Fab. The areas under the curve for digoxin immune Fab were 213-1026 micrograms.h/mL, and total body clearances were 2.3-7.1 mL/min. The total digoxin concentrations peaked at 14-33 times the pre-Fab digoxin concentrations 5-30 hours after digoxin immune Fab administration. In comparing these data with data available from patients with normal renal function, the half-life of digoxin immune Fab and total digoxin was longer, the peak total digoxin concentration occurred later, the ratio of the peak total digoxin concentration to pre-Fab digoxin concentration was larger, and the rebound in free digoxin occurred later in patients with renal impairment. The Fab dose should not be reduced in patients with renal impairment; however, post-Fab monitoring should be extended to compensate for the prolonged half-life of Fab and later rebound of free digoxin.
Similar articles
-
Pharmacokinetic aspects of digoxin-specific Fab therapy in the management of digitalis toxicity.Clin Pharmacokinet. 1995 Jun;28(6):483-93. doi: 10.2165/00003088-199528060-00006. Clin Pharmacokinet. 1995. PMID: 7656506 Review.
-
Disposition of digoxin immune Fab in patients with kidney failure.Clin Pharmacol Ther. 1993 Oct;54(4):388-94. doi: 10.1038/clpt.1993.165. Clin Pharmacol Ther. 1993. PMID: 8222481
-
Influence of digoxin immune Fab therapy and renal dysfunction on the disposition of total and free digoxin.Ann Intern Med. 1993 Aug 15;119(4):273-7. doi: 10.7326/0003-4819-119-4-199308150-00004. Ann Intern Med. 1993. PMID: 8328735
-
Fab antibody fragments: some applications in clinical toxicology.Drug Saf. 2004;27(14):1115-33. doi: 10.2165/00002018-200427140-00004. Drug Saf. 2004. PMID: 15554746 Review.
-
Monitoring serum digoxin concentrations during digoxin immune Fab therapy.DICP. 1991 Oct;25(10):1047-9. doi: 10.1177/106002809102501002. DICP. 1991. PMID: 1803787
Cited by
-
Pharmacokinetic aspects of digoxin-specific Fab therapy in the management of digitalis toxicity.Clin Pharmacokinet. 1995 Jun;28(6):483-93. doi: 10.2165/00003088-199528060-00006. Clin Pharmacokinet. 1995. PMID: 7656506 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical